Halozyme Therapeutics (HALO) PT Raised to $93 at Citizens on Royalty Revenue Growth
Citizens analyst Jason Butler raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $93.00 (from $92.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)